微芯生物：2025年度净利润为5107.57万元

Core Viewpoint - Micron Biomedical (688321.SH) reported a significant turnaround in its financial performance for the fiscal year 2025, achieving a net profit of 51.08 million yuan, driven by strong sales growth in its key products [1] Financial Performance - The company's total operating revenue for 2025 reached 909.54 million yuan [1] - Total profit amounted to 50.84 million yuan [1] - Net profit attributable to shareholders was 51.08 million yuan, marking a return to profitability [1] - The net profit after deducting non-recurring gains and losses was 38.36 million yuan [1] - Earnings per share stood at 0.1252 yuan [1] Product Performance - Sales revenue for the product Sigleptin Sodium increased by approximately 122% year-on-year, attributed to its unique clinical value in "diabetes and liver management" and effective commercialization strategies [1] - Sales revenue for the product Sidabenamine grew by around 16% year-on-year, supported by its recognition in the National Medical Insurance Directory and the addition of a new indication for diffuse large B-cell lymphoma [1] - The product Sidabenamine was included in the latest version of the National Medical Insurance Directory under regular Class B management, which positively impacted its sales despite price reductions and inventory adjustments in the fourth quarter of 2025 [1]